Zepp Health Corp: Form 20-F for the period ended Dec 31, 2021
Filed with the SEC on Apr 28, 2022 and accepted by EDGAR at Apr 28, 2022, 16:55 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $980.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2021-01-01 to 2021-12-31 | $775.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2021-01-01 to 2021-12-31 | $204.9m | us-gaap:GrossProfit |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $80.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2021-01-01 to 2021-12-31 | $14.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2021-01-01 to 2021-12-31 | $7.0m | us-gaap:InterestExpense |
| Income tax | 12 months2021-01-01 to 2021-12-31 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2021-01-01 to 2021-12-31 | $21.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | $0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2021-01-01 to 2021-12-31 | 264,368,629 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$36.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $7.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2021-01-01 to 2021-12-31 | $2.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-12-31 | $230.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $616.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $955.0m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $337.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $494.6m | us-gaap:Liabilities |
| Long-term debt | At period end2021-12-31 | $114.1m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2021-12-31 | $458.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-22-052369. Last ingested by Listed: Nov 5, 2026, 14:06 ET. Listed shows no prices and gives no investment advice.